Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBT Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBT Margin for 11 consecutive years, with 5335.93% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 213738.0% to 5335.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 263126.92% through Dec 2025, up 26322212.0% year-over-year, with the annual reading at 34873.75% for FY2025, 3467552.0% down from the prior year.
  • EBT Margin for Q4 2025 was 5335.93% at Cartesian Therapeutics, up from 6732.55% in the prior quarter.
  • The five-year high for EBT Margin was 5335.93% in Q4 2025, with the low at 6732.55% in Q2 2025.
  • Average EBT Margin over 5 years is 183.93%, with a median of 24.06% recorded in 2021.
  • The sharpest move saw EBT Margin skyrocketed 557767bps in 2024, then tumbled -677749bps in 2025.
  • Over 5 years, EBT Margin stood at 41.34% in 2021, then decreased by -19bps to 33.37% in 2022, then plummeted by -7229bps to 2379.12% in 2023, then skyrocketed by 234bps to 3198.55% in 2024, then skyrocketed by 67bps to 5335.93% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 5335.93%, 6732.55%, and 1806.73% for Q4 2025, Q2 2025, and Q1 2025 respectively.